How effective is the 0.5mg Wegovy dose — and what does the evidence say?

Why 0.25mg appears in the schedule at all

Wegovy's licensed titration pathway runs from 0.25mg to 0.5mg, then 1.0mg, 1.7mg and finally 2.4mg, with roughly four weeks at each level. The 0.5mg step is the first increase after the true starter dose. Its job is not to drive weight loss, it is to let your gut and appetite systems adjust to the medicine at a pace that keeps side effects manageable.

Semaglutide slows gastric emptying and acts on appetite centres in the brain. Both effects intensify as the dose rises. Moving from 0.25mg to 0.5mg already begins to deepen those effects, which is why some people report noticing slightly less hunger or earlier fullness here. If you are curious about whether 0.25mg semaglutide does anything meaningful on its own, we cover that question in detail for anyone who wants to understand the starting dose before moving up. But the magnitude at 0.5mg is modest. The physiological shift that underpins clinically significant weight reduction happens as you move through the upper doses.

The NHS semaglutide medicines page describes the full titration schedule and confirms that 2.4mg is the maintenance dose for weight management, useful to bookmark if you want to check where you are in the ladder at any point.

What the STEP 1 trial actually measured

The pivotal evidence for Wegovy comes from the STEP 1 trial, published in the New England Journal of Medicine, in which adults with obesity received semaglutide 2.4mg weekly for 68 weeks alongside lifestyle support. The average weight reduction was approximately 15% of body weight, a result that informed NICE's recommendation of semaglutide for weight management.

The trial was not designed to measure outcomes at individual titration doses. Participants moved through 0.25mg, 0.5mg, 1.0mg and 1.7mg during the dose-escalation phase before reaching maintenance. No separate arm tested 0.5mg as a long-term dose, so there is no robust clinical figure to quote for weight loss at that level specifically. Presenting one would be misleading.

What the trial does show is that the titration phase itself (the weeks spent at sub-therapeutic doses) was necessary for tolerability. Participants who completed titration and reached maintenance had the outcomes the data describe. Skipping steps or rushing through them tends to increase the side effects that cause people to stop treatment early, which undermines the whole point.

How long most people spend at 0.5mg, and what to expect

Under the standard schedule, 0.5mg lasts four weeks. For most people, that means one pen used at this dose before moving to 1.0mg. Some prescribers slow the pace if GI side effects are significant, which is clinically appropriate. Others may hold a dose for longer if there is a medical reason.

During these early weeks, changes you might notice are shifts in appetite rather than the scales. Meals may feel heavier sooner. Food that was previously appealing may become less so. Those are early signals that the medicine is working as intended, even before weight starts to move. Weighing yourself once a week at the same time of day, under the same conditions, is a simple habit that gives you a reliable picture without the noise of daily fluctuations.

If you are wondering how effective Wegovy 0.25mg is during those earliest weeks, that page looks at what the evidence and clinical experience tell us before the first dose increase. If you are wondering whether the 1.0mg dose marks the point where weight loss becomes more apparent, our page on whether Wegovy 1mg is effective covers the evidence at that stage. For a broader view of how outcomes build across the schedule, our page on what dose of Wegovy is effective sets out the picture across all levels, and which Wegovy dose produces the best results goes further into the details.

On the cost side of things, if you are comparing providers, our guide to Wegovy pricing in the UK explains what a legitimate private price should include (prescription, clinical review, delivery and aftercare) and why that full picture matters more than the headline number.

Side effects at 0.5mg and how they compare to higher doses

The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and burping. At 0.5mg these are generally milder than at maintenance, though not absent. Most are at their worst in the first week or two after each dose increase, then ease as the body adjusts.

The NICE appraisal of semaglutide, TA875, considered the safety profile across the trial data and concluded that the benefit-risk balance supports its use in eligible adults. That appraisal was based on the full treatment period at therapeutic doses, not on the titration phase alone, which is worth keeping in mind when reading it.

If you experience severe, persistent stomach pain that spreads to your back, seek urgent medical attention. This could indicate pancreatitis, which is a rare but serious side effect of GLP-1 medicines. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.

Treatment decisions (including whether to stay at 0.5mg longer, move up, or pause) belong with a prescriber who knows your full picture. Our clinical team at nume reviews every patient's case individually before any step is taken. If you have questions about your titration or want to understand more about your options, speaking to our prescribers is the straightforward next step.